Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Completion of GSK Share Consolidation
The consolidation of GSK shares will become effective at 8.00 a.m. tomorrow
-
Completion of the demerger of Haleon and share consolidation of GSK
Completion of the demerger of Haleon and share consolidation of GSK
-
GSK gathers global experts to discuss role of vaccines in protecting people and the planet
'Palio’ meeting to address growing threat to human health from infectious disease and its links to nature loss and climate change.
-
Result of General Meeting
At a General Meeting on Wednesday 6 July 2022 both resolutions set out in the Notice of General Meeting were duly passed by shareholders.
-
GSK completes acquisition of Sierra Oncology
GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.
-
GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
GSK today announced the first recipient of the Target the Future Think Tank Challenge.
-
Japan’s Ministry of Health, Labour and Welfare accepts Shingrix regulatory submission to prevent shingles in at-risk adults aged 18 years and older
Shingrix was initially approved in 2018 by the Japanese MHLW to prevent shingles in adults aged 50 years or older
-
GSK presents promising new data for bepirovirsen, an investigational treatment for chronic hepatitis B
GSK today announced interim results from the B-Clear phase IIb trial at the EASL International Liver Congress.
-
GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
GSK announced £1bn investment over ten years to accelerate R&D dedicated to infectious diseases
-
GSK to present new data from the B-Clear phase IIb trial for bepirovirsen in chronic hepatitis B at the International Liver Congress 2022
GSK will present 12 abstracts at the European Association for the Study of the Liver’s International Liver Congress 2022.
-
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
GSK today announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial.
-
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients
-
Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon
The proposed Demerger is the most significant corporate change for GSK in the last 20 years
-
GSK publishes Prospectus and Circular for proposed demerger of its Consumer Healthcare business to form Haleon
The Circular is available at www.gsk.com/demerger and the Prospectus is available at www.haleon.com
-
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
Supports development of a strong portfolio of innovative vaccines and specialty medicines
-
ViiV Healthcare announces marketing approval by Japan’s Ministry of Health, Labour and Welfare for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine)
Long-acting treatment enables people living with HIV to reduce the days they receive treatment.
-
GSK announces further appointments to Designate Haleon Board
Demerger and listing of Haleon expected in July 2022
-
China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14 against certain types of cancer-causing human papillomavirus
China’s National Medical Products Administration has approved a two-dose vaccine schedule for Cervarix in girls aged between 9 to 14 years.
-
ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative HIV prevention measure
